Concurrent Investment Advisors’s GSK GSK Stock Holding History

Concurrent Investment Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$865K	Sell	16,496 -19	-0.1%	-$1K	0.01%	1084
2026 Q1	$911K	Sell	16,515 -1,522	-8%	-$82.5K	0.01%	912
2025 Q4	$885K	Sell	18,037 -2,907	-14%	-$136K	0.01%	888
2025 Q3	$904K	Buy	20,944 +246	+1%	+$9.61K	0.02%	684
2025 Q2	$795K	Buy	20,698 +3,841	+23%	+$147K	0.02%	675
2025 Q1	$653K	Buy	16,857 +3,719	+28%	+$136K	0.02%	665
2024 Q4	$444K	Sell	13,138 -5,831	-31%	-$210K	0.01%	703
2024 Q3	$775K	Buy	18,969 +7,080	+60%	+$290K	0.02%	525
2024 Q2	$458K	Buy	11,889 +1,663	+16%	+$70K	0.02%	614
2024 Q1	$438K	Sell	10,226 -140	-1%	-$5.77K	0.02%	583
2023 Q4	$384K	Buy	+10,366	New	+$372K	0.02%	562

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Concurrent Investment Advisors's GSK Position: Q2 2026 in Review

Concurrent Investment Advisors reduced its GSK (GSK) stake by 0.12% in Q2 2026, selling an estimated $1K and leaving 16,496 shares worth $865K. The position accounts for 0.01% of the portfolio, ranked #1084.

Concurrent Investment Advisors first reported a position in GSK in Q4 2023 and has held it in 11 quarters since. The position peaked at $911K in Q1 2026. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Concurrent Investment Advisors held 16,496 shares of GSK worth $865K as of Q2 2026.
Concurrent Investment Advisors sold 19 GSK shares in Q2 2026, an estimated $1K.
GSK made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1084 holding.
Concurrent Investment Advisors first reported a position in GSK in Q4 2023 and has held it in 11 quarters since.
Concurrent Investment Advisors's GSK position peaked at $911K in Q1 2026.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.